Page last updated: 2024-09-04

ampelopsin and Bone Loss, Osteoclastic

ampelopsin has been researched along with Bone Loss, Osteoclastic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Cai, Q; Fan, KJ; Wang, QS; Wang, TY; Wu, J; Xu, BX1
Chen, A; Fang, H; Fang, J; Guo, F; Hou, X; Huang, S; Li, F; Li, X; Zhang, X1

Other Studies

2 other study(ies) available for ampelopsin and Bone Loss, Osteoclastic

ArticleYear
DMY protects the knee joints of rats with collagen-induced arthritis by inhibition of NF-κB signaling and osteoclastic bone resorption.
    Food & function, 2020, Jul-01, Volume: 11, Issue:7

    Topics: Animals; Arthritis, Experimental; Bone Resorption; Cartilage, Articular; Cell Line; Collagen; Flavonols; Knee Joint; Male; NF-kappa B; Osteoblasts; Osteoclasts; RANK Ligand; Rats; Rats, Wistar; Signal Transduction

2020
(2R,3R)Dihydromyricetin inhibits osteoclastogenesis and bone loss through scavenging LPS-induced oxidative stress and NF-κB and MAPKs pathways activating.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:11

    Topics: Animals; Bone Resorption; Flavonols; Lipopolysaccharides; Male; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Osteogenesis; Oxidative Stress; RAW 264.7 Cells; Reactive Oxygen Species; Signal Transduction; Superoxide Dismutase

2018